Polus BioPharm Inc. operates as a biopharmaceutical company in South Korea. Its products in pipeline includes PDP808, an insulin glargine biosimilar for treating diabetes; PDP805, a somatropin biosimilar used for treating growth hormone deficiency; PDP807, a ranibizumab biosimilar for the treatment of macular degeneration; and PDP815, an insulin lispro biosimilar used for treating diabetes. The company was formerly known as Amnis Co., Ltd. and changed its name to Polus BioPharm Inc. in December 2017. Polus BioPharm Inc. was founded in 1972 and is based in Seoul, South Korea.
Research context
Polus BioPharm Inc appears in PyInvesting’s Korea Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- KRW
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
Polus BioPharm Inc is currently in a long term downtrend where the price is trading 0.0% below its 200 day moving average.
From a valuation standpoint, the stock is 56.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.7.
Polus BioPharm Inc's total revenue sank by 89.3% to $234M since the same quarter in the previous year.
Its net income has increased by 75.2% to $-1B since the same quarter in the previous year.
Finally, its free cash flow fell by 4.2% to $-812M since the same quarter in the previous year.
Based on the above factors, Polus BioPharm Inc gets an overall score of 2/5.